Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.
Amidst a complex backdrop of economic crosscurrents and geopolitical tensions, a select group of small-cap companies across Asia are demonstrating remarkable resilience and growth potential. We analyze three standout names from Singapore and China that are navigating the volatility with strong fundamentals.
Asian equities staged a strong recovery on Tuesday, with South Korea's Kospi and Japan's Nikkei leading gains as investors returned to tech stocks. The rebound follows recent volatility, with markets now focused on corporate earnings and geopolitical risks.
The U.S. decision to slash tariffs on Indian goods has been met with cautious optimism by Indian industry, though analysts urge restraint until the full scope of the agreement is clarified.
In a significant diplomatic and economic breakthrough, the U.S. agrees to slash tariffs on Indian goods after Prime Minister Modi commits to halt purchases of Russian crude, easing bilateral tensions and reshaping trade dynamics.
All eyes are on AbbVie as it prepares to release its fourth-quarter earnings. With a history of topping revenue forecasts, the market watches to see if its strategic shifts can continue to deliver amid evolving industry pressures.
Amgen has terminated its collaboration with Kyowa Kirin on the atopic dermatitis drug rocatinlimab, handing full development rights back to the Japanese partner. The strategic shift comes as Amgen's stock trades above most fair value estimates, raising questions about its current valuation amid pipeline recalibration.
Vera Therapeutics appoints industry veteran Matt Skelton as Chief Commercial Officer, signaling a strategic pivot toward commercialization as its lead drug candidate for IgA nephropathy, atacicept, undergoes FDA Priority Review.
All eyes are on Qualcomm as it prepares to release its quarterly earnings. With a strong track record of surpassing estimates, analysts are watching for signs of resilience in the smartphone and IoT markets.
Alphabet's self-driving unit Waymo has raised $16 billion in a landmark funding round, valuing the company at $126 billion. The capital injection, backed by major investors including Alphabet and Dragoneer, is set to fuel an aggressive international expansion of its autonomous ride-hailing service.
Bio-Techne prepares to report quarterly earnings against a backdrop of declining revenue projections and mixed performances from life sciences peers.
The fast-food giant prepares to release its quarterly results as analysts project moderated growth and investors weigh recent performance against sector peers.
All eyes are on Flex (NASDAQ: FLEX) as it prepares to release its fourth-quarter earnings before the market opens on Wednesday. The contract manufacturing leader has consistently outperformed Wall Street's revenue expectations, but can it do so again in a challenging macro environment?
MINISO Group Holding Ltd. (NYSE: MNSO) is capturing investor attention with a potent mix of rapid global store expansion, surging revenue from its TOP TOY brand, and robust cash generation. The company's latest earnings reveal a strategic pivot paying off, even as it navigates the competitive global retail landscape.
Nurix Therapeutics, a clinical-stage biopharma company, is gaining attention for its novel protein degradation platform. With strong early data for its lead drug, key regulatory designations, and strategic partnerships with industry giants, the company is positioning itself to address unmet needs in multi-billion dollar oncology markets.
Twist Bioscience's proprietary silicon-based DNA manufacturing platform is driving double-digit revenue growth and margin expansion, positioning the synthetic biology tools provider on a clear path to adjusted EBITDA breakeven by fiscal 2026.
New late-breaking data for Nektar Therapeutics' lead drug candidate, rezpegaldesleukin, suggests systemic anti-inflammatory benefits in patients with comorbid asthma, potentially expanding its market reach and strengthening the investment case for the biopharma firm.
Cronos Group's stock has rallied on renewed optimism for U.S. cannabis reform. We examine the regulatory shift, strategic positioning, and long-term potential driving investor sentiment.
Amid market volatility, Mettler-Toledo International Inc. (MTD) continues to draw bullish attention for its entrenched role in mission-critical measurement technology across life sciences and industrial sectors. Analysts argue its premium valuation reflects durable competitive advantages rather than market froth.
A year after Hanoi and Washington elevated ties to a Comprehensive Strategic Partnership, an internal Vietnamese military document reveals deep-seated fears of U.S. aggression and 'color revolutions,' highlighting the complex duality at the heart of Vietnam's foreign policy.
